Heterologous expression and characterization of Plasmodium falciparum Merozoite surface protein 1 ([MSP1.sub.42]kDa) in Pichia pastoris and its in-vitro parasite growth inhibition assay.
Using P. pastoris, heterologous proteins can either be expressed intracellularly or secreted into the medium. Because P. pastoris secretes only low levels of endogenous proteins, and because its culture medium contains no added proteins, a secreted heterologous protein comprises the vast majority of the target protein in the medium. Thus, secretion serves as a major first step in purification, separating the foreign protein from the bulk of cellular proteins (23). P. pastoris has the potential of performing many of the post translational modifications typically associated with higher eukaryotes. These include processing of signal sequences, folding, disulfide bridge formation, and both O- and N-linked glycosylation. The combination of strong regulated expression of target gene under control of the AOX1 promoter along with an appropriate media may result in strikingly high levels of foreign proteins in P. pastoris.
MATERIALS AND METHODS
Malaria parasite and yeast strain
Plasmodium falciparum culture was obtained from National Malaria Research Institute, Delhi-110 009 India. The parasite was grown at 37[degrees]C in RPMI medium (Sigma, USA) containing human RBCs; Pichia pastoris GS115 (Invitrogen, USA) was grown at 28[degrees]C in YPD medium (Yeast Extract Peptone Dextrose Medium). For growth on plates, 2 % agar was added to the media. Transformants were grown in media supplemented with 250-1000 [micro]g/ml Geneticin (Sigma, USA). For cloning procedures, Escherichia coli DH5[alpha] was used and grown at 37[degrees]C in LB medium supplemented with 100 [micro]g/ml ampicillin.
Parasite culture and genomic DNA isolation
The P. falciparum culture was grown in RPMI complete medium consisting 5% [AB.sup.+ve] serum, 1% Gentamycin, a drop of freshly prepared human RBC in six well plate. The culture was incubated C[O.sub.2] incubator with 5% C[O.sub.2] at 37[degrees]C until the parasitemia reaches ring stage. The growth of the parasite was monitored by microscopic examination. The parasite culture was harvested and used for genomic DNA extraction. The DNA was isolated using QIA amp DNA mini kit (Qiagen, Germany) as per the instructions of the manufacturer. The DNA was finally eluted from the column in 100[micro]l of elution buffer and stored at -80[degres]C until used further.
Bio-Informatics study on P.falciparum [MSP1.sub.42]kDa protein for B-cell, T-cell epitope and glycosylation prediction
The prediction of linear B-cell epitopes based on seven different parameters viz, hydrophilicity, flexibility, accessibility, turns, exposed surface, polarity and antigenic property was done using
B cepred tool with a threshold of 1.9, 2, 1.9, 2.4, 2.3, 1.8 and 1.9 respectively . T-cell epitope prediction on [MSP1.sub.42]kDa protein was done using ProPred-I and ProPred-II online servers for MHC Class-I and MHC Class-II respectively based on quantitative matrices derived from published literature . The N-linked glycosylation of [MSP1.sub.42]kDa protein was studied using NetNGlyc1.0 server of Technical University of Denmark (http://www.cbs.dtu.dk/services/NetNGlyc).
E. coli and P. pastoris cells were transformed by electroporation. Enzymes SnaB1 and Not I, Sac I and T4DNA ligase (Fermentas, USA), Taq DNA polymerase and reagents for PCR (Invitrogen, USA) were used as recommended by the supplier. Molecular biology protocols were carried out according to Sambrook and Russell . DNA sequencing was performed by ABI DNA sequencer (Applied Biosystems, USA). DNA sequences were analyzed using DNA star software.
Cloning [MSP1.sub.42]kDa gene into pPICK9K yeast transfer vector
The 1125 bp DNA encoding the carboxyl terminal of [MSP1.sub.42]kDa gene from P falciparum (Indian isolates) was amplified from the parasite genomic DNA using high fidelity Pfu polymerase (Fermentas, USA) employing the following primers having introduced SnaB I and Not I sites (bold ad underlined sequences) in the forward and reverse primers respectively. [MSP1.sub.42]kDa forward: 5-'TA TACGTAGCAATATCTGTCACAATGG-3 ' (Nucleotide position+1 to +19 of NCBI accession no FJ919374) and Reverse: 5' TAGCGGCCGCGTTAGAGGAACTGCAGAA-3 ' (Nucleotide position +1125 to +1108 of NCBI accession no FJ919374). The PCR conditions used were: 94[degrees]C for 50 sec, 53[degrees]C for 45 sec, 72[degrees]C for 45sec, for 40 cycles, and finally 72[degrees]C for 10 min. The amplified [MSP1.sub.42]kDa gene fragment was digested with SnaB I and Not I restriction enzymes and was cloned into pPIC9K yeast transfer vector (Invitrogen, USA) at the same restriction sites. The resulting vector pPICK9K[MSP1.sub.42]kDa had the [MSP1.sub.42]kDa gene in frame with the fused Saccharomyces cerevisiae alpha mating factor secretion signal under the control of the methanol-inducible P pastoris alcohol oxidase 1 (AOX1) promoter. The pPICK9K[MSP1.sub.42]kDa was initially transformed into E.coli DH5 a cells (Invitrogen, USA). For selection of the recombinant transformants, the bacterial cells were cultured in Luria-Bertani medium (Himedia, India) supplemented with 50[micro]g/ml ampicillin and 50[micro]g/ml of Kanamycin. The positive bacterial transformants were selected through restriction digestion of plasmid DNA using SnaB I and Not I enzymes and PCR analysis using above [MSP1.sub.42]kDa specific primers. The correct integration of the transgene within the vector was further confirmed through nucleotide sequencing using ABI sequencer.
Integration of pPICK9K[MSP1.sub.42]kDa DNA into P pastoris genome and screening of multi-copy integrants
The recombinant plasmid DNA pPICK9K[MSP1.sub.42]kDa was linearized by digesting with Sac I enzyme to integrate the transgene at His4 locus on the Pichia genome and also to generate [HIS.sup.+], [Mut.sup.+] transformants in P pastoris GS115 cells. Ten microgram of the linier DNA was used to transform fresh electro competent P. pastoris cells via electroporation using Bio-Rad Gene Pulsar Xcell[TM] electroporation system (BioRad laboratories, Inc USA.) at 1492V, 25[micro]F capacitance and 200[degrees]C resistance. After transformation, cells were plated on SD-His plate (1.34% yeast nitrogen base, 2% dextrose, 0.01% complete amino acid supplement minus Histidine, 1M sorbitol supplement, and 2% agar), and incubated at 30[degrees]C for 2 days. The parent plasmid DNA pPIC9K without insert, linearized with Sac I was also transformed similarly for negative control. The colonies obtained were streaked on fresh SD-His plates.
In order to select for transformants containing multiple integrants 100 transformed colonies bearing the chromosomally integrated copies of the pPICK9K[MSP1.sub.42]kDa were screened for multiple copy integrants through replica plating on YPD plates containing different concentrations of Geneticin (250 pg/ml, 500 pg/ml, 750 pg/ml and 1000 pg/ml). Plates were incubated at 30[degrees]C for three days and the growth obtained was scored with plus (+) and minus (-) for the presence or absence of growth respectively on the selection plate as previously described (23). To further confirm the transformants having multiple copy integrants, a total of three Pichia clones were randomly selected from each group of geneticin tolerance. PCR was performed on the genomic DNA isolated from the above clones by employing [MSP1.sub.42]kDa gene specific primers as described earlier (27). Three clones that were found positive through genomic DNA PCR were further sequence confirmed using alpha factor forward and [MSP1.sub.42]kDa reverse primers. Single sequence confirmed Pichia clone that also showed high level resistance to Geneticin (1000 pg/ml) was selected further for subsequent expression study.
Optimization of [MSP1.sub.42]kDa protein expression in Pichia pastoris
In order to have an optimum expression of the recombinant [MSP1.sub.42]kDa protein, different parameters viz, medium, temperature, pH, methanol, induction and harvest period were tested as described earlier (23). The optimized medium and culture conditions were used for subsequent expression of the target recombinant protein in shake flask culture. Briefly, the glycerol stocks of the above Pichia clone was inoculated into 250 ml of YPD (1%Yeast extract, 2%bacto peptone and 2% Dextrose) taken in 2000 ml conical flask along with negative control (Pichia transformed with pPICK9K without insert) and were incubated at 28[degrees]C in a shaker incubator at 250 rpm until the culture reached an [A.sub.600] of 2-3. The cells were harvested by centrifugation at 3,000 x g for 10 min at room temperature and the cell pellets were resuspended in required volume of fresh YPM induction medium (1%Yeast extract, 2% bacto peptone and 2% methanol) so that the final OD at [A.sub.600] was 3. Incubation was continued at 28[degrees]C as above for four days. To sustain induction, required volume of methanol was added to the culture once in every 24 hour. Culture supernatants were collected at different time points ranging from 2496 h (24 h, 48 h, 72 h and 96 h) and the protein was precipitated using equal volume of chilled acetone by centrifuging at 10000 X g for one hour at 4[degrees]C. The protein pellets were resuspended in PBS and further analyzed by running them on 10% polyacrylamide gel electrophoresis under denaturing conditions (26). The gels were subsequently stained with Coomassie Brilliant Blue R-250 (Sigma, USA). The protein concentration was determined through Bradford assay against BSA standards (28).
Characterization of recombinant [MSP1.sub.42]kDa protein through Immunoblotting
The expressed [MSP1.sub.42]kDa protein was reacted with four different human acute phase sera collected from culture confirmed P. falciparum infected patients via immunoblotting. The recombinant protein after separation on SD S-PAGE gel was incubated with 1:500 diluted sera samples individually for one hour at 37[degrees]C. The blot was washed six times in washing buffer (PB S containing 0.025% Tween-20) and further reacted with antihuman IgM horse reddish peroxidase conjugate (Sigma, USA) at 1:5000 dilution for one hour at 37oC. After excessive washing of the blot, the enzymatic color dev elopment was done using [H.sub.2][O.sub.2]/DAB substrate-chromogen.
MALDI-TOF/MS analysis of yeast-derived recombinant MSP 142kDa protein
The [MSP1.sub.42]kDa protein expressed from P pastoris was further confirmed using MALDITOF/MS study. The Coomassie stained recombinant [MSP1.sub.42]kDa recombinant protein was excised from the gel and the gel slices were washed thrice with 200 ql destaining solvent (50% v/v ACN in 25mM NH4 HC[O.sub.3]) with constant vortexing of 10 min. The washed gel pieces were dehydrated with 200ql of 100% ACN and dried in speed-vac centrifuge (Thermo, USA). The protein in the gel slices were subjected to trypsin digestion for overnight. The peptides were extracted and lyophilized for complete removal of the solvent. The pellets obtained were reconstituted sterile triple distilled water and was subsequently purified using Mini Tip C18 micro tips (Sigma, USA). The purified tryptic digest (1 [micro]l) along with equal volume of HCCA matrix was spotted on the MALDI plate. Mass spectrometric analysis was performed using MALDI-TOF instrument (Bruker Microflex LRF-20, Flex Control workstation, Bermen, Germany) equipped with delayed extraction (150 ns) and a UV ionisation laser (N2, 337 nm) with a 3-ns pulse width. The accelerating voltage was 20 kV and the grid voltage was set to 19 kV and laser repetition rate was 20 Hz. For the peptide mass fingerprinting, the instrument was operated in the reflector mode with an average of hundred shots per spectra. Seven hundred laser shots were accumulated and the spectra were evaluated using the Flex Analysis Software (Bruker Daltonics). The MS spectra obtained was submitted to MASCOT search via Bio tools version 3.1. The search parameters used were partial methionine oxidation, one missed cleavage and the database selected was NCBI.
Development of purification method for yeast derived rec.MSP1 protein
After 72.0 h, methanol induced culture was harvested. The culture supernatant was separated from the cells by centrifugation at 5,0009g for 30 min at 4[degrees]C in a swinging bucket rotor using a Sorvall evolution RC centrifuge (Thermo Scientific, USA). Following centrifugation, supernatant was filtered through a 0.45 lm filter. Upon filtration the filtrate was further concentrated approximately ten times using a 10 kDa Molecular weight cut off (MW CO) membrane (Millipore USA). Sodium azide and PMSF were added at the concentrations of 0.05% and 10 mM, respectively, to the final concentrate and stored at -80[degrees]C until used further for purification. Development of purification method on the of anion exchange chromatography was carried out using a 5 mL DEAE Sepharose anion exchange column (Toyo, Japan) in an AKTA explorer system (GE Healthcare, USA) as per the instructions given by the manufacturer. A five ml volume of protein sample was loaded onto a DEAE Sepharose column pre-equilibrated with sterile PBS. For efficient binding of the protein the flow through was reloaded tries on to the column at same flow rate as above. The unwanted proteins were extensively washed using sterile PBS. Following the washing, target proteins were eluted with 0-1M NaCl linear gradient (in sterile PB S) at a flow rate of 1 ml/min. The concerned target protein peaks were collected, concentrate and analyzed by SDS-PAGE for their purity. The concentration of rec. MSP1protein was determined using the Bradford assay (28).
Immunization study of yeast derived MSP1 recombinant protein
Healthy adult male New Zealand White rabbits tested sero negative for Plasmodium falciparum was immunized intramuscularly with 100 qg purified rec. MSP 1 protein in combination with Freund's complete adjuvant (FCA) (Sigma, USA). Subsequent immunizations were carried out with 100 qg purified rec. MSP1 protein combination with Freund's incomplete adjuvant (FIA) (Sigma, USA) at 21 and 42 days of post immunization. Preimmune sera were collected preceding to immunization, 21, 42 and 60 days and stored at 80[degrees]C until further utilization.
In-vitro growth inhibition assay
In vitro parasite growth inhibition assay using pre-immune and immune (tertiary and quaternary bleed) rabbit sera were evaluated for their ability to inhibit parasitic growth in vitro as described previously (34). Briefly, rabbit sera were heat inactivated at 58[degrees]C for 40 min and absorbed with fresh normal human erythrocytes with a equal amount of complete media (90% Incomplete media + 10 inactivated human serum). Human erythrocytes were washed in incomplete media (95.7 % RPMI 1640 + 40 [micro]g/l Gentamycin sulfate + 4.3% Sodium bicarbonate) before use. For in vitro assays purified and dialyzed with PBS rabbit derived anti-MSP1IgG was again dialyzed overnight against RPMI 1640 culture medium. Parasite cultures were synchronized by sorbitol lysis. Infected human erythrocytes were adjusted to an initial parasitemia of 0.5% and a hematocrit of 1.5% in culture medium containing 0.5% complete media. Rabbit preimmune or rabbit derived anti-MSP1IgG were added to infected erythrocyte cultures in a 6-well plate. Cultures were incubated for 72 h, and the parasitemia of Giemsa-stained thin smears of cultured erythrocytes was determined by microscopy.
RESULTS AND DISCUSSION
Malaria parasite culture
Ring-forms of P. falciparum were noticed in the culture initially (fig 1A) followed by which the rings became small trophozoites (fig 1B) and finally schizonts (fig 1C) were observed. Approximately 80-90% of the parasites were in the ring stage of development at 48 h and 72 h during which the culture was harvested for genomic DNA extraction.
Bio-informatics study on P. falciparum [MSP1.sub.42]kDa protein B-cell, T-cell epitope and glycosylation prediction
The linear B-cell epitope prediction on [MSP1.sub.42]kDa protein based on different parameters viz, hydrophilicity, flexibility, accessibility, turns, exposed surface, polarity and antigenic property revealed more than ten potential B-cell specific epitopes that were uniformly distributed all throughout the protein (fig 2). The protein regions having values greater than threshold value and also qualifying at least more than four parameters were considered to be potential epitopes. For T-cell epitope predication, human MHC-I and MHC-II binding regions were identified based on several MHC-Class I alleles (A, B and C) and MHC-Class II alleles (DR, DQ and DP). Numerous peptides within [MSP1.sub.42]kDa protein that crossed threshold peptide score (3%) were found distributed all throughout the protein as seen in figure 3A and 3B. The N-linked glycosylation study of [MSP1.sub.42]kDa protein sequence revealed the presence of two N-linked glycosylation points at amino acid position 281(NISQ) and 326(NPTC) as seen in figure 4. In order to have more number of B-cell and T-cell epitopes for a balanced humoral and cell mediated immune response, whole sequence of [MSP1.sub.42]kDa protein was selected for recombinant expression rather than partial sequence.
Cloning, integration of [MSP1.sub.42]kDa gene into P pastoris genome and screening of multi-copy integrants
The PCR product of DNA encoding the carboxyl terminal of [MSP1.sub.42]kDa gene (1125bp) of P falciparum was inserted at SnaB I-Not I sites into pPICK9K yeast transfer vector under AOX1 promoter in fusion with S. cervecea alpha secretory signal at N-terminus. The resultant pPICK9K[MSP1.sub.42]kDa (fig 5), linearised with Sac I restriction enzyme after transformation in P .pastoris via electroporation yielded 238 His+ transformants per 10pg of DNA used. Upon antibiotic screening of randomly selected 140 transformants at different concentrations of Geneticin, 93 colonies grew at lowest concentration of Geneticin (250 pg/ml). Whereas the selection plates with 500 pg/ml, 750 pg/ml and 1000 pg/ml Geneticin had 86, 85 and 75 colonies respectively (fig 6). As both [Kan.sup.R] and [MSP1.sub.42]kDa gene fragment are integrated together, resistance to Geneticin would give a rough idea on the copy number of the integrated [MSP1.sub.42]kDa gene. Resistance to higher concentrations of geneticin is directly proportional to the copy numbers of kanamycin resistance gene ([Kan.sup.R]) integrated which confers resistance to Geneticin in yeast cells. As reported earlier by us , high copy integrants are due to the multiple gene insertion events at a single locus in Pichia cells that happens spontaneously with a low frequency of all selected His+ transformants. Hence the observed less number of high copy integrants is justified.
Genomic DNA PCR from selected yeast transformants (three from each category) using [MSP1.sub.42]kDa gene specific primers resulted in amplification of approximately 1125 bp product as expected. This confirmed the presence of [MSP1.sub.42]kDa gene fragment within the Pichia genome. As seen in figure 7 only five out of twelve DNA samples amplified the expected 1125 bp DNA. The failure of amplification in the remaining samples may be attributed to the poor quality of the DNA wherein the impurities would have inhibited the PCR amplification. Multiple copy integrant growing of [MSP1.sub.42] kDa gene was selected based on antibiotic sensitivity assay and genomic DNA PCR.
Optimization of [MSP1.sub.42]kDa protein expression in Pichia pastoris
We have employed S. cerevisiae alpha secretory signal (SS) upstream to the target gene in the pPICK9[KMSP1.sub.42] kDa construct. The kex2 protease of Pichia cleaves the fusion tag of the expressed protein resulting in the release of matured fully processed [MSP1.sub.42] kDa protein. The [His.sup.+] [Mut.sup.+] positive Pichia transformant was selected for inducing the expression of the target gene. An optimum expression of the [MSP1.sub.42]kDa recombinant protein of size ~ 42 kDa was noticed after 72 h of post methanol induction (Fig 8). Whereas no specific protein bands were detected in pPICK9K vector transformed yeast and non-induced positive transformant in this region. Studies conducted to improve the expression level with different induction period and methanol concentrations revealed that 72 h of post-induction with 2% methanol concentration is optimum for better expression of [MSP1.sub.42] kDa protein at shake flask level (Data not shown). Upon quantification, the concentration of the [MSP1.sub.42]kDa protein expressed was found to be 45 mg/L of the culture supernatant. However, the level of expression could not be further elevated above this scale with either increased methanol concentration or increased duration of incubation. With the above optimized expression condition, [MSP1.sub.42]kDa was secreted into the medium as a soluble protein. In the present study, the purification tag was avoided in the construct as the previous study by Khan et al  have shown that inclusion of metal ion affinity-tag (Histidine) onto [MSP1.sub.42]kDa affects the specificity of the humoral and cellular immune responses due to differences in the protein fold and epitope accessibility. In light of these findings the soluble secretory [MSP1.sub.42]kDa expressed in the present study is highly advantageous.
Characterization of recombinant [MSP1.sub.42]kDa protein through Immuno-blotting
The recombinant protein obtained from positive Pichia transformants after methanol induction was separated on PAGE gel under denaturing conditions and subsequently transferred onto PVDF membranes. Immunoblotting using four different human patient sera reacted with the recombinant [MSP1.sub.42]kDa protein resulting positive signals (Fig 9). Earlier report  has reported that the native conformation of the C-terminal region of MSP-1 of Plasmodium is crucial for the protective immune response. Hence the conformational integrities of the yeast derived [MSP1.sub.42]kDa is established on the basis of its reactivity with P falciparum infected patient sera. It is important to note that the bacterial expressed [MSP1.sub.42]kDa resulted in considerable loss of reactivity with the patient sera due to the reduction of the disulde bonds in the recombinant protein (31,32). Hence our derived [MSP1.sub.42]kDa is more beneficial over bacterially expressed proteins that have been reported earlier.
MALDI-TOF/MS analysis of yeast-derived recombinant [MSP1.sub.42]kDa protein
As no MSP-1 specific monoclonal antibodies were available in the present study to characterize the yeast expressed recombinant protein, we have employed an advanced MALDITOF/MS technique to further confirm its authenticity as described earlier (33). The 42kDa protein band corresponding to recombinant [MSP1.sub.42]kDa protein was enzymatically digested as described under methodology section. As shown in figure 10, peptide mass profiles were obtained from the destained band. Twenty peptides (range 800-2750 Da) were used for peptide mass database search which identified [MSP1.sub.42]kDa protein with 55% sequence coverage of the published P.falciparum [MSP1.sub.42]kDa protein sequence (Table 1) upon mascot search thus establishing the identity of the yeast expressed [MSP1.sub.42]kDa.
Development of purification method of recombinant [MSP1.sub.42]kDa protein
Anion exchange chromatography The anion-exchange chromatography was selected seeing that rec.MSP1 is recognized to bind to an anion exchanger. The sterile PBS buffer was used in the present study offers a high binding competence of rec. MSP1 protein and also good resolution. Following the binding four column volume gentle wash was applied with sterile PB S. Consequently elution of protein on the anion-exchange column was succeeded in the optimized range of 200-225 mM NaCl as shown in (Fig. 11). Fractions corresponding to the protein peak eluted using gradient NaCl showed a single protein band on SDS-PAGE as seen in (Fig. 12). The concentration of the purified protein (50.0 mg/L) was estimated by the Bradford assay. Immunization of rabbits with yeast derived MSP1 recombinant protein
To evaluate the elicitation of P.falciparum parasite inhibiting antibodies against the yeast expressed rec. MSP1protein, rabbits were immunized intramuscularly. Collected Pre immune and post immunized, sera (42 and 60 days) were assayed for anti-MSP 1 antibody titers. An antibody titer were interestingly increased in the both immunized rabbits with recombinant MSP1 while not in immunized with Freund's adjuvant plus sterile PBS (control rabbit). High antibody titer of 1:150000 after six weeks of booster injection and 1: 160000 after nine weeks of booster injection were observed (data not shown). The end point titer was set at 0.21, which were more than four standard deviations. These results clearly show that the recombinant MSP1 protein expressed in Pichia pectoris was highly immunogenic and inducing a specific antibody response.
In-vitro parasite growth inhibition
Immune sera of immunized rabbit was obtained after the third and fourth of immunization for distinguish promising effects on in vitro parasite growth. In this present in vitro growth inhibition assay, parasite growth inhibition was obtained for purified anti-MSP1IgG (Fig.13) of both rabbit vaccinated sera at a final concentration of 300 [micro]g/ml [data not shown]. A maximum parasitemia was noted for the preimmune rabbit sera and control immunized sera because control rabbit was immunized with adjuvant. To binary confirmation with the intention of the observed parasite growth inhibition was rabbit derived anti-MSP1 IgG mediated, inhibition experiments for the two clinically known positive samples were also performed [data not shown]. High levels of growth inhibition ([??] 95%) were obtained. The experiments were executed using purified rabbit derived anti-MSP 1 IgG three times with identical results (data not shown).
The MSP-1 protein expressed on the surface of invasive merozoites of Plasmodium is an important target for the development of an effective malaria vaccine. The bulk economical production of this glycosylated [MSP1.sub.42]kDa protein requires a simple and reliable eukaryotic system. In the present study, Pichia pastoris, a most popular eukaryotic host has been successfully employed for expressing P. falciparum [MSP1.sub.42]kDa protein. Purification strategy was developed and purity of protein verified by SDS-PAGE electrophoresis. Immunization of rabbit with recombinant [MSP1.sub.42]kDa in complete and incomplete Freund's adjuvant were revealed high antibody titers against the recombinant [MSP1.sub.42]kDa. Rabbit derived anti-MSP 1IgG inhibited in vitro parasite growth, indicating that this inhibition was anti-MSP 1IgG mediated. The multi-copy recombinant Pichia transformant obtained in the present study has an immense industrial application for large scale production of [MSP1.sub.42]kDa recombinant protein for either prophylactic or diagnostic applications.
The authors also acknowledge Director, DRDE, Gwalior, Madhya Pradesh-474 002 for his kind support in executing this study. We acknowledge the support rendered by Dr. PVL Rao, Director, DRDO-BU Centre for Life Sciences, Bharathiar University Campus, Coimbatore-641046 in executing the study. The authors are also thankful to Dr. B.K. Bhattacharya, Head, Div. of Biochemistry, DRDE, Gwalior for his help on MALDI-TOF/MS study.
(1.) Snow, R.W.; Guerra, C.A.; Noor, A.M.; Myint, H.Y; Hay, S.I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature, 2005, 434, 214-217.
(2.) Richard, L.; Shimp, Jr.; Laura, B.; Yanling, M.Z.; Brain, S.; Henderson, D.P.; MacDonald, N.J.; Lebowitz, J.; Saul, A.; Narum, D.L. Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42kDa merozoite Surface protein 1 ([MSP1.sub.42]) in the absence of an affinity tag. Pro. Exp. Purif., 2006, 50, 58-67.
(3.) Richie, T.L.; Saul, Progress and challenges for malaria vaccine. Nature, 2002, 415, 694-701.
(4.) Dvorak, J.A.; Miller, L.H.; Whitehouse, W.C.; Shiroshi, T. Invasion of erythrocyte by malaria merozoite. Science, 1975, 187, 748-750.
(5.) Aikawa, M.; Miller, L.H.; Johnson, J.; Rabbege, J. Erytrocyte enter by malarial parasite, A moving junction between erythrocyte and parasite. J. Cell Biol., 1978, 77, 72-82.
(6.) Pichyangkul, S.; Gettayacamin, M.; Miller, R.S.; Lyon, J.A.; Angov, E.; Tongtawe, P.; Ruble, D.L.; Heppner Jr, D.G.; Kester, K.E.; Ballou, W.R.; Diggs, C.L.; Voss, G.; Cohen, J.D.; Walsh, D.S. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP142 formulated with novel aduvent or with alum. Vaccine, 2004, 22, 3831-3840.
(7.) Cowman, A.F.; Crabb, B.S. Invasion of red blood cell by malaria parasite. Cell, 2006, 124 (4), 755-766.
(8.) Gilson, P.R.; O- Donnell, R.A.; Nebl, T.; Senders, P.R.; Wicham, M.E. MSP1 (19) miniproteins can serve as targets for invension inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking. Mol. Microbial, 2008, 68, 124-138.
(9.) McBride, J.S.; Heidrich, H.G. Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoite form an antigenic complex. Mol. Biochem. Parasitol., 1987, 23(1), 71-84.
(10.) Blackman, M.J.; Ling, I.T.; Nicholls, S.C.; Holder, A. A. Proteolytic Processing of the Plasmodium falciparum merozoite surface protein1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol. Biochem. Parasitol., 1991, 49, 29-33.
(11.) Blackman, M.J.; NScott-Finnigan, T.J.; Shai, S.; Holder, A.A. Antibodies inhibit the protease--mediated processing of a malaria merozoite surface protein. J. Exp. Med., 1994, 180, 389-93.
(12.) Chang, S.P.; Gibson, H.L.; Lee-Ng, C.T.; Barr, P. J.; Hui, G.S. A Carboxyl terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J. Immunol., 1992, 149, 548-55.
(13.) Gozalo, A.; Lucas, C.; Cachay, M.; et al. Passive transfer of growth-inhibitory antibodies raised against yeast-expressed recombinant Plasmodium falciparum merozoite surface proteinl (19). Am. J. Trop. Med. Hyg., 1995, 59, 991-7.
(14.) Kumar, S.; Yadava, A.; Keister, D.B.; et al. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aoutus monkeys. Mol. Med., 1995, 1, 325-32.
(15.) Chang, S.P.; Case, S.E.; Gosnell, W.L.; et al. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein1 protects Aoutus monkeys against malaria. Infect. Immun., 1996, 64, 253-61.
(16.) Egan, A. F.; Chappel, J.A.; Burghaus, P.A.; Morris, J.S.; McBride, J.S.; Holder, A.A.; Kaslow, D.C.; Riley, E.M. Serum antibodies from malaria exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP-1 19, the carboxy-terminal fragment of the maj or merozoite surface protein ofPlasmodium falciparum. Infect. Immun., 1995, 63, 456-466.
(17.) Kumar, S.; Collins, W.; Egan, A.; et al. Immunogenicity and efficacy in aoutus monkays of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect. Immun., 2000, 68, 2215-23.
(18.) Stower, A.W.; Cioce, V; Shimp, R.L.; et al. Efficacy of two alternate vaccine based on Plasmodium falciparum vaccine of merozoite surface protein 1anAoutus challenge trial. Infect. Immun., 2001, 69, 1536-46.
(19.) Lalitha, P. V; Biswas, S.; Pillai, C.R.; Seth, R.K.; Saxena, R.K. Expression, purification and characterization of allelic variants of MSP-1(42) from Indian Plasmodium falciparum isolates. Vaccine, 2010, 28(29), 4661-67.
(20.) Alaro, J.R.; Angov, E.; Lopez, A.M.; Zhou, H.; Long, C.A.; Burns, J.M. Jr. Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8. Infect. Immun., 2012, 80(7), 2473-84.
(21.) Pan, W.; Ravot, E.; Tolle, R.; Frank, R.; Mosbach, R.; Turbachova, I.; Bujard, H. Vaccine candidate MSP-1 from Plasmodium falciparum: a redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia coli and mammalian cells. Nucleic Acids Res., 1999, 27(4), 1094-103.
(22.) Zong, S.; Kron, M.W.; Epp, C.; Engler, T.; Bujard, H.; Kochanek, S.; Kreppel, F. AE1 and high-capacity adenoviral vectors expressing full-length codon-optimized merozoite surface protein 1 for vaccination against Plasmodium falciparum. J. Gene Med., 2011, 13(12), 670-9. doi: 10.1002/jgm.1627
(23.) Athmaram, T.N.; Saraswat, S.; Santhosh, S.R.; Singh, A.K.; Suryanarayana, V.V.S.; Priya, R.; Gopalan, N.; Parida, M.M.; Rao, P.V.L.; Vijayaraghavan, R. Yeast expressed recombinant Hemagglutinin protein of Novel H1N1 elicits neutralizing antibodies in rabbits and mice. Virology J., 2011, 8, 524.
(24.) Saha, S.; Raghava, G.P.S. BcePred: Prediction of Continuous B-Cell Epitopes in Antigenic Sequences Using Physico-chemical Properties. LNCS 3239, In G.Nicosia, V.Cutello, P. J. Bentley and J. Timis, Eds., ICARIS, Springer, 2004, pp.197-204.
(25.) Singh, H.; Raghava, G.P.S. ProPred: Prediction of HLA-DR binding sites. Bioinformatics, 2001, 17(12), 1236-37.
(26.) Sambrook, J.; Russell, D.W. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 2002.
(27.) Athmaram, T.N.; Saraswat, S.; Singh, A.K.; Rao, M.K.; Gopalan, N.; Suryanarayana, V.V.; Rao, P. V Influence of copy number on the expression levels of pandemic influenza hemagglutinin recombinant protein in methylotrophic yeast Pichia pastoris. Virus Genes, 2012, 42, DOI 10.1007/s11262-012-0809-7.
(28.) Bradford, M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 1976, 72, 248-254.
(29.) Khan, F.; Legler, P.M.; Mease, R.M.; Duncan, E.H.; Bergmann-Leitner, E.S.; Angov, E. Histidine affinity tags affect MSP 1(42) structural stability and immunodominance in mice. Biotechnol. J., 2012, 7(1), 133-47
(30.) Ling, I.T.; Ogun, S.A.; Holder, A.A. Immunization against malaria with a recombinant protein. Parasite Immunol., 1994, 16, 63-67.
(31.) Sachdeva, S.; Ahmad, G.; Malhotra, P.; Mukherjee, P.; Chauhan, V.S. Comparison of Immunogenicities of Recombinant Plasmodium vivax Merozoite Surface Protein 1 19- and 42-Kilodalton Fragments Expressed in Escherichia coli. Infect. Immun., 2004, 72, 5775-5782
(32.) Egan, A.F.; Blanckman, M.J.; Kaslow, D.C. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed and/or -rechallenged Aoutus vociferans monkeys. Infect. Immun., 2000, 68, 1418-27.
(33.) Athmaram, T.N.; Singh, A.K.; Saraswat, S.; Shrivastava, S.; Misra, P.; Rao, M.K.; Gopalan, N.; Rao, P.V.L. A simple Pichia pastoris fermentation and downstream processing strategy for making recombinant pandemic Swine Origin Influenza A virus Hemagglutinin protein. J. Ind. Microbiol. Biotechnol., 2012, DOI 10.1007/s10295-012-1220-z
(34.) Hui, G. S. N., Hashimoto A., and Chang S. P.. Roles of conserved and allelic regions of the maj or merozoite surface protein (gp195) in immunity against Plasmodium falciparum. Infect. Immun. 1992.60:1422-1433.
Anil K. Singh , Saurabh Shrivastava , M. Kameswara Rao , Kshitij chandel , Hotam singh Chaudhary , Prativa K Behara , C.R. Pillai  and N Gopalan  *
 Bio-process Scale up Facility, Defence Research and Development Establishment, Ministry of Defence (Govt. of India), Gwalior-474002, India.
 Biochemistry Division, Defence Research and Development Establishment, Ministry of Defence (Govt. of India), Gwalior-474002, India.
 ISPAT General Hospital, Rourkela-769005, Odisha, India.
 Madhav Institute of Technology and Science, Gwalior, India
 National Institute of Malaria Research, Delhi-110009, India.
 Vector Management Division, Defence Research and Development Establishment, Ministry of Defence (Govt. of India), Gwalior-474 002, India.
 F.B.D, DFRL, Siddarthanagar, Mysore- 570 011 Ministry of Defence (Govt. of India), Gwalior-474 002, India.
(Received: 04 June 2015; accepted: 10 August 2015)
* To whom all correspondence should be addressed. Mob.: +91-9179936322; E-mail: firstname.lastname@example.org
Caption: Fig. 1. Microscopic examination ofP falciparum parasite at different stages of growth: (A) Ring-forms of stage (B) trophozoite stage (C) Schizonts stage
Caption: Fig. 2. B-cell epitope prediction: B-cell epitope prediction on [MSP1.sub.42]kDa protein based on different parameters viz, hydrophilicity, flexibility, accessibility, turns, exposed surface, polarity and antigenic property. The predicted B-cell linier epitopes are in blue underlined
Caption: Fig. 3. T-cell epitope predication on [MSP1.sub.42]kDa protein : (A) Human MHC-Class I binding regions (B) MHC-Class II binding regions. Amino acid regions crossing the peptide score threshold of 3% are considered to be potential T-cell epitopes.
Caption: Fig 4. Prediction of N-linked glycosylation on [MSP1.sub.42]kDa protein: Blue lines indicate the potential N-linked glycosylation points at amino acid position 281(NISQ) and 326(NPTC)
Caption: Fig. 5. Schematic representation of pPIC9K[MSP1.sub.42]kDa plasmid DNA: The expression cassette of consists of P. falciparum [MSP1.sub.42] kDa gene cloned under AOX1 promoter and has Alpha secretory signal (SS) at amino terminal end. The plasmid has ampicicillin resistance gene ([Amp.sup.R]) for selection in bacteria and kanamycin resistance gene ([Kan.sup.R]) that confers resistance to Geneticin for selection in yeast
Caption: Fig. 6. Geneticin sensitivity assay: Pichia transformants were selected on different concentrations of geneticin (250[micro]g/ml, 500[micro]g/ml, 750[micro]g/ml and 1000[micro]g/ml) via replica plate method. Growth obtained were scored as '+' or '-' after three days.
Caption: Fig. 7. Genomic DNA PCR: Pichia transformants were subjected to genomic DNA PCR using [MSP1.sub.42]kDa specific primers
Caption: Fig. 8. SDS-PAGE profile of [MSP1.sub.42]kDa protein from culture supernatant of positive Pichia transformant after methanol induction
Caption: Fig. 9. Immunoblots of yeast derived [MSP1.sub.42]kDa protein using human sera samples
Caption: Fig. 10. MALDI-TOF/MS spectrum of yeast derived [MSP1.sub.42]kDa protein tryptic digests in reflectron mode using HCCA as matrix
Caption: Fig. 11. Chromatogram of an anion exchange base purification of recombinant [MSP1.sub.42]kDa protein using the AKTA explorer FPLC system
Caption: Fig. 12. SDS-PAGE analysis of purified recombinant [MSP1.sub.42]kDa protein by an anion exchange chromatography
Caption: Fig. 13. SDS-PAGE analysis of purified Anti-MSP1IgG protein by affinity chromatography
Table 1. List of tryptic peptides that showed homology to that of P. falciparum MSP142kDa protein in the Peptide mass fingerprint obtained from MALDI-TOF study SI. Position Measured Theoretical Mass Miss No (start- mass mass error cleavege end) (m+H)+ (m+) (ppm) 1 57-63 831.4869 830.4796 35.9 0 2 75-82 933.54 932.5327 94.0 0 3 167-174 934.4567 933.4495 2.8.8 0 4 209-216 946.5316 945.5243 11.8 1 5 64-71 966.5943 965.587 33.6 1 6 175-183 1040.545 1039.538 -27.5 1 7 156-164 1106.751 1105.744 128 0 S 184-193 1117.757 1116.75 132 1 9 165-174 1133.705 1132.698 126 1 10 189-198 1177.686 1176.679 34.1 1 11 27B-288 1310.7802 1309.7729 106 1 12 72-82 1337.8788 1336 8715 138 1 13 57-68 1400.7978 1399 7905 -9.26 1 14 29-42 1706.0537 1705.0465 141 0 15 28-42 1834.1509 1833.1436 132 1 16 222-238 1845 0938 1844.0866 24.9 0 17 138-155 2153.3422 2152.3349 82.7 0 IB 239-257 2231.4258 2230 4185 132 1 19 75-93 2249.3054 2248.2981 109 1 20 284-309 2722.4742 2721.4670 146 1 SI. Peptide sequence No 1 K.LLNSEQK.N 2 K.ESVENDIK.F 3 K.INDCNVEK.D 4 K.LINDDTKK.D 5 K.NTLLKSYK.Y 6 K.DEAHVKITK.L 7 K.IDDYLINLK.A S K.LSDLKAIDDK.I 9 K.AKINDCNVEK.D 10 K.AIDDKIDLFK.N 11 K.CLLIMYKQEGDK.C 12 K.YIKESVENDIK.F 13 K.LLNSEQKNTLLK.S 14 K.YFLDGLESDLMQFK.H 15 R.KYFLDGLESDLMQFK.H 16 K.LLSTGLVQNFPNTIISK.L 17 K.FLPFLTNIETLYNNLVNK.I IB K.LIEGKFQDMLNISQHQCVK.K 19 K.ESVENDIKFAQEGISYYEK.V 20 K.ESVENDIKFAQEGISYYEK.V .C
|Printer friendly Cite/link Email Feedback|
|Author:||Singh, Anil K.; Shrivastava, Saurabh; Rao, M. Kameswara; Chandel, Kshitij; Chaudhary, Hotam singh; B|
|Publication:||Journal of Pure and Applied Microbiology|
|Date:||Dec 1, 2015|
|Previous Article:||Study of association between Helicobacter pylori infection and microalbuminuria in type-2 diabetic patients.|
|Next Article:||Mitigating effect of salicylic acid on biochemical and antioxidant enzymes in maize (Zea mays L.) genotypes under low temperature stress.|